Invasive Quagga mussel Is Rewriting Switzerland’s Waterscape
Send us Fan Mail A fingernail‑sized invader is transforming Swiss lakes and the cost of clean water. In this episode, we track the quagga mussel from its arrival in the Rhine to its rapid spread throu...
17 Feb 13min
Bonus Episode - The Trends Shaping the Pharmaceutical Industry in 2026
Send us Fan Mail Join host, Jo Fahy, and pharmaceuticals and healthcare reporter, Jessica Davis Pluss, to weigh up the forces shaping pharma in 2026. From AI’s real gains in clinics and labs, to the c...
3 Feb 15min
Bonus Episode - Inside Switzerland’s Quiet Rise as a Longevity Hub
Send us Fan Mail How did longevity go from a social media trend to a focus of serious science? In this special bonus episode our host, Jo Fahy, is joined in the studio by pharmaceuticals and healthcar...
27 Jan 25min
Special announcement: Season wrap for longevity, please try out Lost Cells
Send us Fan Mail Lost cells on Apple, Spotify and any where you listen to your podcasts. SWI swissinfo.ch is a public service media company based in Bern, Switzerland.
16 Des 20253min
Rethinking Aging: Science, Society, And The Stories We Tell
Send us Fan Mail Want a longer life that still feels like yours? We sit down with psychologist Christina Röcke of the University of Zurich’s Healthy Longevity Center to unpack what actually fuels heal...
2 Des 202519min
How Michael Hall’s TOR Discovery Reframed Longevity Science
Send us Fan Mail We trace how a soil-derived drug led to the discovery of mTOR, why growth control sits at the core of aging biology, and where evidence ends for humans. Michael Hall’s quiet breakthro...
25 Nov 202517min
Big Pharma steps up race for AI-discovered drugs
Send us Fan Mail What if the most valuable drug candidates aren’t found but designed on demand? We follow a chemist’s journey from a pencil-and-paper notebook to generative algorithms that propose nov...
18 Nov 202515min
Women’s Health Meets Drug Design and Medical Research
Send us Fan Mail We trace how sex and gender shape drug development, from male-heavy mouse studies to the split results in Lecanemab’s Alzheimer’s trial. Experts explain why regulators should keep app...
11 Nov 202517min
